Видео ютуба по тегу Nct03575351

NCT JNJM : Which one is your best side?
NCT JNJM : Which one is your best side?
Dr Kamdar on the Long-Term Efficacy of Liso-Cel in R/R LBCL
Dr Kamdar on the Long-Term Efficacy of Liso-Cel in R/R LBCL
Long-term follow-up of TRANSFORM: liso-cel versus SOC for R/R LBCL
Long-term follow-up of TRANSFORM: liso-cel versus SOC for R/R LBCL
Evaluating the role of autoSCT vs CAR-T in LBCL: expert insights & advice for community oncologists
Evaluating the role of autoSCT vs CAR-T in LBCL: expert insights & advice for community oncologists
3-year follow-up from the TRANSFORM trial: liso-cel is superior to SoC in R/R DLBCL
3-year follow-up from the TRANSFORM trial: liso-cel is superior to SoC in R/R DLBCL
The value of CAR-T cell therapy in R/R DLBCL
The value of CAR-T cell therapy in R/R DLBCL
2026 TAEYONG CONCERT ❮TY TRACK - REMASTERED❯ Peak Track
2026 TAEYONG CONCERT ❮TY TRACK - REMASTERED❯ Peak Track
TRANSFORM: liso-cel versus standard of care as second-line therapy for R/R LBCL
TRANSFORM: liso-cel versus standard of care as second-line therapy for R/R LBCL
Treatment strategies for patients with DLBCL who relapse after CAR-T therapy
Treatment strategies for patients with DLBCL who relapse after CAR-T therapy
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
Rationale of TRANSFORM: liso-cel vs SOC in patients with high-risk R/R NHL
Rationale of TRANSFORM: liso-cel vs SOC in patients with high-risk R/R NHL
CAR-T therapy in second-line for NHL: ZUMA-7, TRANSFORM & BELINDA
CAR-T therapy in second-line for NHL: ZUMA-7, TRANSFORM & BELINDA
The role of CAR-T therapy in hematologic malignancies
The role of CAR-T therapy in hematologic malignancies
Real-world safety and efficacy of liso-cel in R/R large B-cell lymphoma
Real-world safety and efficacy of liso-cel in R/R large B-cell lymphoma
The impact of CAR-T therapy in the second-line setting in lymphoma
The impact of CAR-T therapy in the second-line setting in lymphoma
Approval of axi-cel in second-line for R/R LBCL & label update
Approval of axi-cel in second-line for R/R LBCL & label update
Terapia CAR-T en segunda línea en linfoma de células B
Terapia CAR-T en segunda línea en linfoma de células B
Current treatment landscape of DLBCL
Current treatment landscape of DLBCL
Lymphoma highlights from ASH 2021
Lymphoma highlights from ASH 2021
Updates in DLBCL from ASH 2021
Updates in DLBCL from ASH 2021